Cook Meredith sold $38K of ANIP
Cook Meredith (SR. VP, GENERAL COUNSEL & SEC.) sold 500 shares of ANI PHARMACEUTICALS INC (ANIP) at $75.48 on 2026-08-13 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed event is an open-market sale of 500 shares at a stated price, executed under a pre-arranged Rule 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.
Market read
Traders may note the insider sale for sentiment monitoring, but there is no accompanying fundamental catalyst in the text.
What to watch
The article does not provide prior sale history, total planned volume, or whether the sale is part of a larger multi-tranche program, limiting inference.
Background
The article is a SEC Form 4 insider transaction disclosure for ANI Pharmaceuticals, reported by Meredith Cook (SR. VP, General Counsel & SEC).
Ticker impact
ANI Pharmaceuticals disclosed a Form 4 showing Meredith Cook sold 500 shares at $75.48 on 2026-08-13 under a 10b5-1 plan.
Likely minimal impact; any reaction should be muted unless accompanied by other company-specific news.
The filing is an open-market sale by an officer, explicitly tied to a pre-arranged 10b5-1 plan, and the article provides no new operational or financial developments.
Market effects
No clear sector read-through from a single routine 10b5-1 insider sale.
None indicated.
None indicated.
Counterpoint
Insider selling can still reflect private risk perceptions, even when executed via 10b5-1, especially if sales accelerate versus prior patterns.
Key entities
- issuerANI Pharmaceuticals Inc
Company whose insider transaction was disclosed on Form 4.
- insiderMeredith Cook
Senior VP, General Counsel & SEC, who sold shares.